Properties
What is it?
International Nonproprietary Name - latanoprost Clinical-pharmacological group: Ophthalmology → Anti-glaucoma agents → For topical use in ophthalmology Dosage form: 0.005% eye drops Description: Colorless, transparent solution. Composition 1 ml of the preparation contains: Active substance: latanoprost 0.05 mg Excipients: disodium hydrogen phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, benzalkonium chloride, purified water. Pharmacotherapeutic group: Anti-glaucoma agent. Prostaglandin. Indications for use: - Elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension, including when other intraocular pressure-lowering agents are not tolerated or are insufficiently effective. Contraindications: - Hypersensitivity to the components of the preparation. Side effects: Local reactions: Eye irritation (burning, itching, foreign body sensation after instillation) may develop, as well as thickening, lengthening, and darkening of eyelashes. In 1-10% of patients, conjunctival hyperemia, transient punctate epithelial erosions, blepharitis, increased iris pigmentation, and eye pain are observed. In less than 1% of patients: skin rash, eyelid edema. Other: darkening of eyelid skin, corneal edema and erosions, iritis, uveitis, macular edema, including cystic (mainly in patients with aphakia, pseudophakia, posterior capsule rupture, or increased risk of developing macular edema). Method of administration and dosage: For topical use only. The preparation is instilled into the conjunctival sac of the affected eye, 1 drop once a day, in the evening. If a dose is missed, the next instillation of the preparation is carried out according to the usual schedule (the dose is not doubled). When used with other topical ophthalmic agents, the interval between instillations should be at least 10 minutes. Overdose: Symptoms: Eye irritation, conjunctival or episcleral hyperemia. Treatment: Symptomatic. Interaction with other medicinal products: Latanoprost is pharmaceutically incompatible with thiomersal, as precipitation may occur. The preparation can be used with agents that reduce intraocular pressure (timolol, adrenomimetics, acetazolamide, pilocarpine). Special instructions: Latanoprost can cause a change in eye color by increasing the amount of brown pigment in the iris. This effect is mainly observed in patients with mixed iris coloration, which is explained by an increase in melanin content in the stromal melanocytes of the iris. In patients with uniform eye color, a change in eye color was observed very rarely after 2 years of using the preparation. The color change is not accompanied by any clinical symptoms or pathological changes. After discontinuation of the preparation, further increase in the amount of brown pigment was not observed, however, the already changed color may be irreversible. In the presence of iris lentigo or nevus, no changes were observed during therapy. Before starting treatment, patients should be informed about the possibility of a change in eye color. If there is an intense change in eye pigmentation, treatment may be discontinued. Treatment of only one eye can lead to the development of permanent heterochromia. Latanoprost should not be used more than once a day, as its effectiveness decreases with frequent use. Latanoprost should be used with caution in cases of active inflammatory processes of the eyeball (iritis, uveitis), aphakia, pseudophakia with damage to the lens capsule. When using soft contact lenses, the lenses should be removed before instillation; lenses can be inserted 15-20 minutes after using the medication.
